Suboptimal responders have increased risk for incident cardiovascular disease
The addition of monthly evolocumab to statin therapy for individuals with hypercholesterolemia or mixed dyslipidemia and type 2 diabetes led to significant reductions in low-density lipoprotein cholesterol.
Objective short sleep duration is associated with daytime sleepiness, whereas obstructive sleep apnea is associated with obesity, dyslipidemia, and hypertension.
Colchicine is safe and effective at improving obesity-associated inflammatory measures among adults with obesity and metabolic syndrome without diabetes.
This post hoc analysis is the first to suggest that evolocumab increases the apolipoprotein A1 remnant ratio following 12 weeks of treatment.
For patients with type 1 and type 2 diabetes, the lung is often overlooked as a target organ.
People living with HIV and declining cognition exhibit hyperinsulinemia, as well as abnormal cholesterol and lipid metabolism.
There is an opportunity to increase statin use by improving physician recognition of statin-eligible patients.
Metabolic syndrome biomarkers have been validated as predictors of World Trade Center-related lung injury.
Lipid-lowering was associated with an increased risk for stroke in secondary prevention trials alone.
Amarin has submitted a supplemental New Drug Application (sNDA) for Vascepa (icosapent ethyl) to reduce the risk of major cardiovascular (CV) events in the statin-treated population. Icosapent ethyl is a single-molecule consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. It is currently indicated as an adjunct to diet to reduce triglyceride…